WDR88 Inhibitors
Chemical inhibitors of WDR88 act through various mechanisms to inhibit its function within cellular signaling pathways. Wortmannin and LY294002 are specific inhibitors of phosphoinositide 3-kinases (PI3K), which play a pivotal role in the PI3K/AKT pathway, often associated with cellular growth and survival signals. By inhibiting PI3K, these chemicals can prevent the activation of downstream effectors that may be essential for the functions of WDR88, thereby inhibiting its role in the cell. The inhibition by Go6976, a potent inhibitor of Protein Kinase C (PKC), suggests that if WDR88's function is mediated through PKC-dependent pathways, its activity would be disrupted upon the inhibition of PKC. Similarly, ML7 targets myosin light chain kinase (MLCK), an enzyme involved in cytoskeletal organization. WDR88's role in processes dependent on MLCK activity would be affected by ML7, leading to inhibition of its function in cytoskeletal dynamics.
Further, SB203580 and PD98059 inhibit p38 MAP kinase and MEK, respectively, which are components of the MAPK signaling pathway. If WDR88 relies on p38 MAPK or ERK signaling for its function, the inhibition of these kinases would disrupt the signaling cascade involving WDR88. SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), and Y-27632, a selective inhibitor of Rho-associated protein kinase (ROCK), both target kinases that could regulate WDR88 through their respective pathways. The inhibition of JNK or ROCK would likely lead to a decrease in WDR88's activity in processes regulated by these pathways. U73122, which inhibits phospholipase C (PLC), and BAPTA-AM, a calcium chelator, disrupt calcium-dependent signaling. Since WDR88 may be regulated by such signaling, their use can lead to an inhibition of WDR88's role in calcium-mediated pathways. Additionally, KN-93 and PP2, inhibitors of calcium/calmodulin-dependent protein kinase II (CaMKII) and Src family tyrosine kinases, respectively, affect WDR88's associated functions by inhibiting these kinases, which may be upstream regulators of WDR88's activity within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a specific covalent inhibitor of phosphoinositide 3-kinases (PI3K). WDR88 is known to be involved in cellular processes that are regulated by PI3K signaling. Inhibition of PI3K can lead to reduced activity of downstream signaling pathways, which in turn could inhibit the cellular processes WDR88 is involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another well-known inhibitor of PI3K. By inhibiting PI3K, LY294002 would prevent the phosphorylation of downstream molecules in the signaling pathway, which is necessary for the functions WDR88 is associated with. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $223.00 | 8 | |
Go6976 is a potent inhibitor of Protein Kinase C (PKC). Since WDR88 is implicated in pathways that require PKC activity for signal transduction, inhibition of PKC by Go6976 could result in the inhibition of WDR88's functional role within these pathways. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
ML7 is an inhibitor of myosin light chain kinase (MLCK). WDR88 is involved in cytoskeletal organization processes that are dependent on MLCK activity. By inhibiting MLCK, ML7 can indirectly inhibit the function of WDR88 by disrupting the cytoskeletal dynamics. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. If WDR88 functions are modulated by p38 MAPK-dependent signaling pathways, inhibition of this kinase by SB203580 could result in the functional inhibition of WDR88. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which is upstream of ERK in the MAPK signaling pathway. As WDR88 might be involved in ERK-mediated signaling processes, inhibition of MEK by PD98059 would inhibit ERK activation and consequently inhibit the role of WDR88 in these pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). WDR88, if involved in JNK-mediated signaling pathways, would be functionally inhibited by SP600125 through the disruption of JNK signaling. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of Rho-associated protein kinase (ROCK). WDR88 is potentially involved in pathways regulated by ROCK, and thus, its inhibition by Y-27632 could lead to the inhibition of WDR88's function related to cytoskeletal organization. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
BAPTA-AM is an intracellular calcium chelator. Given that WDR88 may be regulated by calcium-dependent signaling pathways, the chelation of intracellular calcium by BAPTA-AM can inhibit WDR88's functional role in these pathways. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
KN-93 is an inhibitor of calcium/calmodulin-dependent protein kinase II (CaMKII). If WDR88 functions are regulated by CaMKII, then inhibition of this kinase by KN-93 could inhibit WDR88's role within the cell. | ||||||